First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men

BACKGROUND: Bleeding is a clinically significant issue with all current anticoagulants. Safer antithrombotic strategies are required. OBJECTIVES: To investigate the safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, a humanized, factor XI (FXI)‐directed monoclonal antibody, after single...

Descripción completa

Detalles Bibliográficos
Autores principales: Nowotny, Bettina, Thomas, Dirk, Schwers, Stephan, Wiegmann, Sara, Prange, Wolfgang, Yassen, Ashraf, Boxnick, Stefanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
THROMBOSIS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320929/
https://www.ncbi.nlm.nih.gov/pubmed/35490404
http://dx.doi.org/10.1111/jth.15744

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320929/
https://www.ncbi.nlm.nih.gov/pubmed/35490404
http://dx.doi.org/10.1111/jth.15744

Ejemplares similares